BIOMAT Database Logo BIOMAT Database Logo

Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. 1995

M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
Merck Research Laboratories, West Point, Pa 19486.

We investigated the effects of angiotensin II (Ang II) type 1 receptor blockade with losartan on the renin-angiotensin-aldosterone system in hypertensive patients (supine diastolic blood pressure, 95 to 110 mm Hg). Qualifying patients (n = 51) were allocated to placebo, 25 or 100 mg losartan, or 20 mg enalapril. Blood pressure, plasma drug concentrations, and renin-angiotensin-aldosterone system mediators were measured on 4 inpatient days: end of placebo run-in, after first dose, and 2 and 6 weeks of treatment. Plasma drug concentrations were similar after the first and last doses of losartan. At 6 weeks, 100 mg losartan and 20 mg enalapril showed comparable antihypertensive activity. Four hours after dosing, compared with the run-in day, 100 mg losartan increased plasma renin activity 1.7-fold and Ang II 2.5-fold, whereas enalapril increased plasma renin activity 2.8-fold and decreased Ang II 77%. Both drugs decreased plasma aldosterone concentration. For losartan, plasma renin activity and Ang II increases were greater at 2 than at 6 weeks. Effects of losartan were dose related. After the last dose of losartan, plasma renin activity and Ang II changes were similar to placebo changes by 36 hours. These results indicate that long-term blockade of the feedback Ang II receptor in hypertensive patients produces modest increases of plasma renin activity and Ang II that do not appear to affect the antihypertensive response to the antagonist.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004656 Enalapril An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. Enalapril Maleate,MK-421,MK421,Renitec,Renitek,MK 421,Maleate, Enalapril
D005260 Female Females

Related Publications

M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
Effects of losartan, an angiotensin II receptor antagonist, on the fibrinolytic system in hypertensive patients.
July 1999, International journal of hematology,
M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats.
January 1992, Life sciences,
M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
Studies on the renin-angiotensin-aldosterone system in elderly hypertensive patients with an angiotensin II antagonist.
November 1979, Clinical science (London, England : 1979),
M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
Influence of nonpeptide angiotensin II receptor antagonist, losartan, on neurogenic vasoconstriction.
May 1995, Journal of cardiovascular pharmacology,
M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
Monoclonal antibodies to the nonpeptide angiotensin II receptor antagonist, losartan.
June 1992, European journal of pharmacology,
M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients.
November 2001, Hypertension research : official journal of the Japanese Society of Hypertension,
M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
Effect of Losartan, a nonpeptide angiotensin II receptor antagonist, on drinking behavior and renal actions of centrally administered renin.
April 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.
January 1993, American journal of hypertension,
M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
The effects of saralasin, an angiotensin II antagonist, on blood pressure and the renin-angiotensin-aldosterone system in normal and hypertensive subjects.
August 1976, Australian and New Zealand journal of medicine,
M R Goldberg, and T E Bradstreet, and E J McWilliams, and W K Tanaka, and S Lipert, and T D Bjornsson, and S A Waldman, and B Osborne, and L Pivadori, and G Lewis
Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
July 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
Copied contents to your clipboard!